OA13075A - Sustained released delivery of amphetamine salts. - Google Patents

Sustained released delivery of amphetamine salts. Download PDF

Info

Publication number: OA13075A
Authority: OA; OAPI
Prior art keywords: amphétamine; pharmaceutical composition; sait; profile; sustained
Prior art date: 2002-09-24

Application number

OA1200500086A

Other languages

English (en)

Inventor

Beth Burnside

Rong-Kun Chang

Richard A Couch

Original Assignee

Shire Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-24

Filing date

2003-09-24

Publication date

2006-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31996998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-24 Application filed by Shire Lab Inc filed Critical Shire Lab Inc

2006-11-10 Publication of OA13075A publication Critical patent/OA13075A/en

Links

KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title claims abstract description 7
230000002459 sustained effect Effects 0.000 title claims description 8
239000000203 mixture Substances 0.000 claims abstract description 55
239000012730 sustained-release form Substances 0.000 claims abstract description 35
238000013268 sustained release Methods 0.000 claims abstract description 33
238000009472 formulation Methods 0.000 claims abstract description 23
230000036470 plasma concentration Effects 0.000 claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 claims abstract 21
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract 8
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract 8
238000000576 coating method Methods 0.000 claims description 36
150000003839 salts Chemical class 0.000 claims description 32
239000011248 coating agent Substances 0.000 claims description 31
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
208000013403 hyperactivity Diseases 0.000 claims description 8
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
229960000632 dexamfetamine Drugs 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 5
VHKVKWTWHZUFIA-DGOKBZBKSA-N (2s)-1-phenylpropan-2-amine;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound C[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O VHKVKWTWHZUFIA-DGOKBZBKSA-N 0.000 claims description 4
229940052370 dextroamphetamine saccharate Drugs 0.000 claims description 4
229940119751 dextroamphetamine sulfate Drugs 0.000 claims description 4
238000004090 dissolution Methods 0.000 claims description 4
229940025084 amphetamine Drugs 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
LBXRPPWPQUZKBO-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O LBXRPPWPQUZKBO-DKWTVANSSA-N 0.000 claims 3
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical group [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
230000001105 regulatory effect Effects 0.000 claims 1
150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
229940047812 adderall Drugs 0.000 abstract description 23
230000000541 pulsatile effect Effects 0.000 abstract description 4
239000011324 bead Substances 0.000 description 38
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 26
239000003814 drug Substances 0.000 description 25
229940079593 drug Drugs 0.000 description 23
229920000642 polymer Polymers 0.000 description 20
-1 polyethylene Polymers 0.000 description 17
239000003826 tablet Substances 0.000 description 16
239000001856 Ethyl cellulose Substances 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
229920001249 ethyl cellulose Polymers 0.000 description 15
235000019325 ethyl cellulose Nutrition 0.000 description 15
239000007921 spray Substances 0.000 description 14
238000000034 method Methods 0.000 description 12
210000002381 plasma Anatomy 0.000 description 12
239000000047 product Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000000843 powder Substances 0.000 description 9
229920002678 cellulose Polymers 0.000 description 8
239000001913 cellulose Substances 0.000 description 8
235000010980 cellulose Nutrition 0.000 description 8
239000006185 dispersion Substances 0.000 description 8
239000000463 material Substances 0.000 description 8
238000011282 treatment Methods 0.000 description 8
239000010410 layer Substances 0.000 description 7
239000002245 particle Substances 0.000 description 7
239000008188 pellet Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 6
229920003134 Eudragit® polymer Polymers 0.000 description 5
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 5
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000012729 immediate-release (IR) formulation Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000001069 triethyl citrate Substances 0.000 description 5
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
235000013769 triethyl citrate Nutrition 0.000 description 5
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 4
MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
206010012289 Dementia Diseases 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
229920002301 cellulose acetate Polymers 0.000 description 4
229960004170 clozapine Drugs 0.000 description 4
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
230000006872 improvement Effects 0.000 description 4
229960002296 paroxetine Drugs 0.000 description 4
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 4
229940020965 zoloft Drugs 0.000 description 4
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 3
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000002051 biphasic effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960002896 clonidine Drugs 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
229940098766 effexor Drugs 0.000 description 3
229940011681 elavil Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
206010016256 fatigue Diseases 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229960002048 guanfacine Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
229960005017 olanzapine Drugs 0.000 description 3
229940055692 pamelor Drugs 0.000 description 3
229940035613 prozac Drugs 0.000 description 3
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
229940039925 zyprexa Drugs 0.000 description 3
BUCORZSTKDOEKQ-UHFFFAOYSA-N 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine Chemical compound C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 BUCORZSTKDOEKQ-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010002942 Apathy Diseases 0.000 description 2
229920008347 Cellulose acetate propionate Polymers 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229920003161 Eudragit® RS 30 D Polymers 0.000 description 2
LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
208000019022 Mood disease Diseases 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
208000005439 Sleep paralysis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
229920002494 Zein Polymers 0.000 description 2
BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
229940039856 aricept Drugs 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
229940116224 behenate Drugs 0.000 description 2
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229920006217 cellulose acetate butyrate Polymers 0.000 description 2
239000011247 coating layer Substances 0.000 description 2
229940099242 dexedrine Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
229940108366 exelon Drugs 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
230000036541 health Effects 0.000 description 2
ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 2
JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
229940009622 luvox Drugs 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
239000008185 minitablet Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
229940087524 nardil Drugs 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 2
229940106887 risperdal Drugs 0.000 description 2
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
229940099204 ritalin Drugs 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
229940035004 seroquel Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
229940090016 tegretol Drugs 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
229920003176 water-insoluble polymer Polymers 0.000 description 2
239000001993 wax Substances 0.000 description 2
229940009065 wellbutrin Drugs 0.000 description 2
239000005019 zein Substances 0.000 description 2
229940093612 zein Drugs 0.000 description 2
GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 description 1
KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
MHNSPTUQQIYJOT-UHFFFAOYSA-N 3-(6h-benzo[c][1]benzoxepin-11-ylidene)propyl-dimethylazanium;chloride Chemical compound Cl.C1OC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 MHNSPTUQQIYJOT-UHFFFAOYSA-N 0.000 description 1
WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
101150108431 CLDN4 gene Proteins 0.000 description 1
208000001573 Cataplexy Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
102100038447 Claudin-4 Human genes 0.000 description 1
QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
244000194101 Ginkgo biloba Species 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
241000404146 Minois Species 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
101710171573 Primary amine oxidase Proteins 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940072359 anaprox Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940072698 ativan Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229940057922 carbatrol Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
HKQOBOMRSSHSTC-UHFFFAOYSA-N cellulose acetate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 HKQOBOMRSSHSTC-UHFFFAOYSA-N 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960005228 clioquinol Drugs 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000009500 colour coating Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000007771 core particle Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229940075922 depacon Drugs 0.000 description 1
229940075925 depakote Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
229940064790 dilantin Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940084238 eldepryl Drugs 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940095895 haldol Drugs 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940073092 klonopin Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229950005223 levamfetamine Drugs 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
229940061871 lorcet Drugs 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
238000003801 milling Methods 0.000 description 1
229960004644 moclobemide Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 description 1
229940087480 norpramin Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
229940000596 parlodel Drugs 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
229940088507 permax Drugs 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229940117394 provigil Drugs 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
229960003770 reboxetine Drugs 0.000 description 1
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical group [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
229940099190 serzone Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
XYGBKMMCQDZQOZ-UHFFFAOYSA-M sodium;4-hydroxybutanoate Chemical compound [Na+].OCCCC([O-])=O XYGBKMMCQDZQOZ-UHFFFAOYSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013269 sustained drug release Methods 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
229940072690 valium Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229940000146 vicodin Drugs 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000009736 wetting Methods 0.000 description 1
229940074158 xanax Drugs 0.000 description 1
229940051225 xyrem Drugs 0.000 description 1
229940083488 zonalon Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

OA1200500086A 2002-09-24 2003-09-24 Sustained released delivery of amphetamine salts. OA13075A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41279902P	2002-09-24	2002-09-24
US10/353,073 US6913768B2 (en)	2002-09-24	2003-01-29	Sustained release delivery of amphetamine salts

Publications (1)

Publication Number	Publication Date
OA13075A true OA13075A (en)	2006-11-10

Family

ID=31996998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500086A OA13075A (en)	2002-09-24	2003-09-24	Sustained released delivery of amphetamine salts.

Country Status (29)

Country	Link
US (2)	US6913768B2 (es)
EP (1)	EP1542660B1 (es)
JP (1)	JP2006503071A (es)
KR (1)	KR20050084589A (es)
CN (1)	CN1684668B (es)
AP (1)	AP2030A (es)
AT (1)	ATE495731T1 (es)
AU (1)	AU2003272619B2 (es)
BR (1)	BR0314486A (es)
CA (1)	CA2499546C (es)
CR (1)	CR7766A (es)
CY (1)	CY1112335T1 (es)
DE (1)	DE60335807D1 (es)
DK (1)	DK1542660T3 (es)
EA (1)	EA018082B1 (es)
EC (1)	ECSP055702A (es)
ES (1)	ES2360046T3 (es)
HR (1)	HRP20050356A2 (es)
IL (1)	IL167470A (es)
IS (1)	IS2814B (es)
MA (1)	MA27469A1 (es)
MX (1)	MXPA05003129A (es)
NO (1)	NO336938B1 (es)
NZ (1)	NZ539216A (es)
OA (1)	OA13075A (es)
PL (1)	PL375991A1 (es)
SI (1)	SI1542660T1 (es)
WO (1)	WO2004028509A1 (es)
ZA (1)	ZA200502406B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010055613A1 (en) *	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US20020068078A1 (en)	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US8394813B2 (en)	2000-11-14	2013-03-12	Shire Llc	Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en)	2001-08-22	2006-01-19	Travis Mickle	Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en)	2003-09-30	2007-01-30	New River Pharmaceuticals Inc.	Compounds and compositions for prevention of overdose of oxycodone
US7700561B2 (en) *	2002-02-22	2010-04-20	Shire Llc	Abuse-resistant amphetamine prodrugs
US7105486B2 (en) *	2002-02-22	2006-09-12	New River Pharmaceuticals Inc.	Abuse-resistant amphetamine compounds
US7659253B2 (en)	2002-02-22	2010-02-09	Shire Llc	Abuse-resistant amphetamine prodrugs
WO2004071501A1 (en) *	2003-02-10	2004-08-26	Shire Biochem Inc.	Enantiomeric amphetamine compositions for the treatment of adhd
WO2004091483A2 (en)	2003-04-07	2004-10-28	Shire Laboratories, Inc.	Once daily formulations of tetracyclines
MXPA05012850A (es) *	2003-05-29	2006-05-17	New River Pharmaceuticals Inc	Compuestos de anfetamina resistentes al abuso.
ME00391B (me) *	2003-08-08	2011-10-10	Biovail Laboratories Int Srl	Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
EP1827385B1 (en)	2004-11-23	2013-03-27	Adamas Pharmaceuticals, Inc.	Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en)	2004-11-24	2013-03-05	Adamas Pharmaceuticals, Inc	Composition and method for treating neurological disease
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
AU2006232896A1 (en) *	2005-04-06	2006-10-12	Mallinckrodt Inc.	Matrix-based pulse release pharmaceutical formulation
JP5666087B2 (ja)	2005-04-06	2015-02-12	アダマス・ファーマシューティカルズ・インコーポレーテッド	Ｃｎｓ関連疾患の治療のための方法及び組成物
CN102488652B (zh) *	2006-03-16	2014-06-18	特瑞斯制药股份有限公司	含有药物-离子交换树脂复合物的经修饰释放的制剂
AU2007238858A1 (en) *	2006-04-10	2007-10-25	Shire Llc	Mono and di-substituted oxycodone compounds and compositions
US20070253927A1 (en) *	2006-04-13	2007-11-01	Gwenaelle Jegou	Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
WO2007120864A2 (en) *	2006-04-14	2007-10-25	Shire Llc	Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US8846100B2 (en)	2006-05-12	2014-09-30	Shire Llc	Controlled dose drug delivery system
JP5052602B2 (ja)	2006-05-12	2012-10-17	シャイアエルエルシー	制御用量薬物送達システム
KR100774613B1 (ko) *	2006-05-26	2007-11-12	한국화학연구원	수불용성 고분자로 이루어진 서방형 약물 전달체
US20080069871A1 (en) *	2006-07-21	2008-03-20	Vaughn Jason M	Hydrophobic abuse deterrent delivery system
US20080207668A1 (en) *	2006-10-06	2008-08-28	New River Pharmaceuticals Inc.	Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
US20080090771A1 (en) *	2006-10-06	2008-04-17	Shire Llc	Abuse-resistant hydrocodone compounds, compositions and methods of using the same
EP2124556B1 (en)	2006-10-09	2014-09-03	Charleston Laboratories, Inc.	Pharmaceutical compositions
WO2008103538A1 (en) *	2007-02-21	2008-08-28	Connected Health Systems, Llc	Treating adhd and other diseases involving inflammation
US20080268047A1 (en) *	2007-04-24	2008-10-30	Xavier University Of Louisiana	Controlled Release Multiple Layer Coatings
ES2620672T3 (es)	2008-01-09	2017-06-29	Charleston Laboratories, Inc.	Comprimidos de doble capa que comprenden oxicodona y prometazina
KR20100126465A (ko) *	2008-03-05	2010-12-01	파나세아 바이오테크 리미티드	미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
WO2011006012A1 (en)	2009-07-08	2011-01-13	Charleston Laboratories Inc.	Pharmaceutical compositions
GB201002612D0 (en) *	2010-02-16	2010-03-31	Jagotec Ag	Improvements in or relating to organic compounds
US9511037B2 (en)	2010-04-23	2016-12-06	Genco Sciences Llc	Compositions for reduction of side effects
PL2560624T3 (pl)	2010-04-23	2019-01-31	Kempharm, Inc.	Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
US9498447B2 (en)	2011-03-23	2016-11-22	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en)	2011-03-23	2014-12-23	Ironshore Pharmaceuticals & Development, Inc.	Methods for treatment of attention deficit hyperactivity disorder
DK3272342T3 (da) *	2011-03-23	2021-06-07	Ironshore Pharmaceuticals & Dev Inc	Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US9119809B2 (en)	2011-03-23	2015-09-01	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en)	2011-03-23	2021-02-02	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en)	2011-03-23	2017-03-28	Ironshore Pharmaceuticals & Development, Inc.	Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en)	2011-03-23	2022-02-08	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en)	2011-03-23	2015-01-06	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en)	2011-03-23	2016-03-15	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en)	2011-03-23	2019-05-21	Ironshore Pharmaceuticals & Development, Inc.	Methods of treatment of attention deficit hyperactivity disorder
WO2013003622A1 (en)	2011-06-28	2013-01-03	Neos Therapeutics, Lp	Dosage forms for oral administration and methods of treatment using the same
CA2880456A1 (en)	2012-08-15	2014-02-20	Tris Pharma, Inc.	Methylphenidate extended release chewable tablet
EP2906208B1 (en) *	2012-10-09	2019-01-30	Sears, Douglas	Therapeutic treatment
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
MA43532A (fr)	2015-12-30	2018-11-07	Adamas Pharmaceuticals Inc	Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
JP2019507181A (ja)	2016-03-04	2019-03-14	チャールストンラボラトリーズ，インコーポレイテッド	医薬組成物
US11602512B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en)	2016-07-22	2021-05-11	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en)	2016-07-22	2025-11-25	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en)	2016-07-22	2022-11-22	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es)	2016-07-22	2017-11-30	Flamel Ireland Ltd	Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en)	2016-07-22	2024-05-21	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3072764A1 (en)	2017-08-24	2019-02-28	Adamas Pharma, Llc	Amantadine compositions, preparations thereof, and methods of use
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
CN113473980A (zh)	2019-03-01	2021-10-01	弗拉梅尔爱尔兰有限公司	在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
KR20220009954A (ko)	2019-04-17	2022-01-25	컴퍼스 패쓰파인더 리미티드	신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US11583510B1 (en)	2022-02-07	2023-02-21	Flamel Ireland Limited	Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en)	2022-02-07	2023-10-10	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB768512A (en)	1954-08-16	1957-02-20	Smith Kline & French Internat	Improvements in or relating to pharmaceutical tablets
US4049791A (en) *	1974-06-21	1977-09-20	Delco Chemical Company, Inc.	Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents
FR2470599A1 (fr) *	1979-12-07	1981-06-12	Panoz Donald	Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US5002776A (en) *	1983-12-22	1991-03-26	Elan Corporation, Plc	Controlled absorption diltiazem formulations
IE56999B1 (en) *	1983-12-22	1992-03-11	Elan Corp Plc	Pharmaceutical formulation
US5364620A (en) *	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4894240A (en) *	1983-12-22	1990-01-16	Elan Corporation Plc	Controlled absorption diltiazem formulation for once-daily administration
US4917899A (en) *	1983-12-22	1990-04-17	Elan Corporation Plc	Controlled absorption diltiazem formulation
US4728512A (en) *	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
EP0227814A1 (en)	1985-07-02	1987-07-08	The Upjohn Company	Therapeutic formulations with bimodal release characteristics
GB8518301D0 (en) *	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
EP0212747B1 (en)	1985-08-16	1991-04-10	The Procter & Gamble Company	Drug particles having constant release and immediate release
JPS62103012A (ja) *	1985-10-23	1987-05-13	Eisai Co Ltd	多重顆粒
US5011692A (en) *	1985-12-28	1991-04-30	Sumitomo Pharmaceuticals Company, Limited	Sustained pulsewise release pharmaceutical preparation
US4723958A (en) *	1986-05-23	1988-02-09	Merck & Co., Inc.	Pulsatile drug delivery system
DE3712095A1 (de) *	1987-04-10	1988-10-20	Lentia Gmbh	Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
DE3827214A1 (de) *	1988-08-11	1990-02-15	Roehm Gmbh	Retardierte arzneiform und verfahren zu ihrer herstellung
US5275819A (en) *	1989-02-06	1994-01-04	Amer Particle Technologies Inc.	Drug loaded pollen grains with an outer coating for pulsed delivery
DK0384646T3 (da)	1989-02-16	1993-07-12	British Tech Group	Dispenseringsindretning
KR920702383A (ko) *	1989-08-28	1992-09-03	원본미기재	치료제의 방출을 조절하는데 유용한 생부식성 중합체
JPH0674206B2 (ja) *	1989-12-28	1994-09-21	田辺製薬株式会社	放出制御型製剤およびその製法
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5156850A (en) *	1990-08-31	1992-10-20	Alza Corporation	Dosage form for time-varying patterns of drug delivery
US5232705A (en) *	1990-08-31	1993-08-03	Alza Corporation	Dosage form for time-varying patterns of drug delivery
ZA92543B (en) *	1991-01-30	1992-10-28	Alza Corp	Osmotic device for delayed delivery of agent
US5226902A (en) *	1991-07-30	1993-07-13	University Of Utah	Pulsatile drug delivery device using stimuli sensitive hydrogel
US5407686A (en) *	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US5308348A (en) *	1992-02-18	1994-05-03	Alza Corporation	Delivery devices with pulsatile effect
US5260068A (en) *	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
EP0653935B1 (en) *	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Pelletised pharmaceutical composition
US5260069A (en) *	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
JP2916978B2 (ja) *	1993-08-25	1999-07-05	エスエス製薬株式会社	放出開始制御型製剤
US5395626A (en) *	1994-03-23	1995-03-07	Ortho Pharmaceutical Corporation	Multilayered controlled release pharmaceutical dosage form
US5582855A (en) *	1994-07-01	1996-12-10	Fuisz Technologies Ltd.	Flash flow formed solloid delivery systems
FR2723536A1 (fr) *	1994-08-11	1996-02-16	Seth Pawan	Composition permettant une liberation selective d'un principe actif
US5731314A (en) *	1995-01-06	1998-03-24	Bencherif; Merouane	Pharamceutical compositions for prevention and treatment of tourette's syndrome
CA2223629A1 (en)	1995-07-14	1997-02-06	Nicholas Robert Pope	Therapeutic use of d-threo-methylphenidate
US5837284A (en) *	1995-12-04	1998-11-17	Mehta; Atul M.	Delivery of multiple doses of medications
US5922736A (en) *	1995-12-04	1999-07-13	Celegene Corporation	Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) *	1995-12-04	1999-06-01	Celgene Corporation	Method of treating attention deficit disorders with d-threo methylphenidate
HRP970493A2 (en) *	1996-09-23	1998-08-31	Wienman E. Phlips	Oral delayed immediate release medical formulation and method for preparing the same
US5891474A (en) *	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
US5840329A (en) *	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
US5885616A (en) *	1997-08-18	1999-03-23	Impax Pharmaceuticals, Inc.	Sustained release drug delivery system suitable for oral administration
US6210705B1 (en)	1997-12-15	2001-04-03	Noven Pharmaceuticals, Nc.	Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6372254B1 (en)	1998-04-02	2002-04-16	Impax Pharmaceuticals Inc.	Press coated, pulsatile drug delivery system suitable for oral administration
US5945123A (en) *	1998-04-02	1999-08-31	K-V Pharmaceutical Company	Maximizing effectiveness of substances used to improve health and well being
US20010055613A1 (en) *	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
EP1126826B3 (en) *	1998-11-02	2019-05-15	Alkermes Pharma Ireland Limited	Multiparticulate modified release composition of methylphenidate
US6673367B1 (en)	1998-12-17	2004-01-06	Euro-Celtique, S.A.	Controlled/modified release oral methylphenidate formulations
US6419960B1 (en)	1998-12-17	2002-07-16	Euro-Celtique S.A.	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
EP1165054A4 (en) *	1999-04-06	2005-02-09	Pharmaquest Ltd	PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
US6384020B1 (en) *	1999-07-14	2002-05-07	Shire Laboratories, Inc.	Rapid immediate release oral dosage form
CA2477004C (en) *	2002-02-22	2011-05-10	Thomas Piccariello	Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2004071501A1 (en) *	2003-02-10	2004-08-26	Shire Biochem Inc.	Enantiomeric amphetamine compositions for the treatment of adhd
US8846100B2 (en) *	2006-05-12	2014-09-30	Shire Llc	Controlled dose drug delivery system

2003
- 2003-01-29 US US10/353,073 patent/US6913768B2/en not_active Expired - Lifetime
- 2003-09-24 AU AU2003272619A patent/AU2003272619B2/en not_active Ceased
- 2003-09-24 KR KR1020057005127A patent/KR20050084589A/ko not_active Withdrawn
- 2003-09-24 NZ NZ539216A patent/NZ539216A/en not_active IP Right Cessation
- 2003-09-24 ZA ZA200502406A patent/ZA200502406B/xx unknown
- 2003-09-24 AT AT03754811T patent/ATE495731T1/de active
- 2003-09-24 ES ES03754811T patent/ES2360046T3/es not_active Expired - Lifetime
- 2003-09-24 MX MXPA05003129A patent/MXPA05003129A/es active IP Right Grant
- 2003-09-24 HR HR20050356A patent/HRP20050356A2/xx not_active Application Discontinuation
- 2003-09-24 DE DE60335807T patent/DE60335807D1/de not_active Expired - Lifetime
- 2003-09-24 WO PCT/US2003/029757 patent/WO2004028509A1/en not_active Ceased
- 2003-09-24 EA EA200500530A patent/EA018082B1/ru not_active IP Right Cessation
- 2003-09-24 JP JP2004540151A patent/JP2006503071A/ja active Pending
- 2003-09-24 SI SI200331985T patent/SI1542660T1/sl unknown
- 2003-09-24 DK DK03754811.2T patent/DK1542660T3/da active
- 2003-09-24 CA CA002499546A patent/CA2499546C/en not_active Expired - Lifetime
- 2003-09-24 EP EP03754811A patent/EP1542660B1/en not_active Expired - Lifetime
- 2003-09-24 AP AP2005003275A patent/AP2030A/xx active
- 2003-09-24 BR BR0314486-0A patent/BR0314486A/pt not_active Application Discontinuation
- 2003-09-24 OA OA1200500086A patent/OA13075A/en unknown
- 2003-09-24 PL PL03375991A patent/PL375991A1/xx not_active Application Discontinuation
- 2003-09-24 CN CN038227029A patent/CN1684668B/zh not_active Expired - Fee Related
2005
- 2005-01-07 US US11/030,174 patent/US20050158384A1/en not_active Abandoned
- 2005-03-16 IL IL167470A patent/IL167470A/en active IP Right Grant
- 2005-03-18 CR CR7766A patent/CR7766A/es unknown
- 2005-03-21 MA MA28168A patent/MA27469A1/fr unknown
- 2005-03-23 EC EC2005005702A patent/ECSP055702A/es unknown
- 2005-04-22 NO NO20051986A patent/NO336938B1/no not_active IP Right Cessation
- 2005-04-22 IS IS7818A patent/IS2814B/is unknown
2011
- 2011-04-15 CY CY20111100379T patent/CY1112335T1/el unknown

Also Published As

Publication number	Publication date
CA2499546C (en)	2008-05-20
IS2814B (is)	2012-11-15
CN1684668A (zh)	2005-10-19
CR7766A (es)	2007-07-10
HRP20050356A2 (en)	2005-10-31
DK1542660T3 (da)	2011-05-16
MA27469A1 (fr)	2005-08-01
KR20050084589A (ko)	2005-08-26
SI1542660T1 (sl)	2011-06-30
MXPA05003129A (es)	2005-10-05
JP2006503071A (ja)	2006-01-26
DE60335807D1 (de)	2011-03-03
HK1075828A1 (en)	2005-12-30
WO2004028509A1 (en)	2004-04-08
NZ539216A (en)	2008-02-29
AU2003272619A1 (en)	2004-04-19
NO336938B1 (no)	2015-11-30
EP1542660B1 (en)	2011-01-19
US20050158384A1 (en)	2005-07-21
ATE495731T1 (de)	2011-02-15
IL167470A (en)	2010-06-30
NO20051986D0 (no)	2005-04-22
EP1542660A1 (en)	2005-06-22
AU2003272619B2 (en)	2008-10-09
CN1684668B (zh)	2010-05-26
EA200500530A1 (ru)	2005-10-27
AP2030A (en)	2009-08-24
US20040059002A1 (en)	2004-03-25
EA018082B1 (ru)	2013-05-30
ECSP055702A (es)	2006-01-27
CY1112335T1 (el)	2015-12-09
PL375991A1 (en)	2005-12-12
ES2360046T3 (es)	2011-05-31
BR0314486A (pt)	2005-08-02
US6913768B2 (en)	2005-07-05
NO20051986L (no)	2005-06-24
IS7818A (is)	2005-04-22
CA2499546A1 (en)	2004-04-08
AP2005003275A0 (en)	2005-06-30
ZA200502406B (en)	2005-10-04

Publication	Publication Date	Title
OA13075A (en)	2006-11-10	Sustained released delivery of amphetamine salts.
US9173857B2 (en)	2015-11-03	Controlled dose drug delivery system
US10881618B2 (en)	2021-01-05	Compositions for treatment of attention deficit hyperactivity disorder
ES2529455T3 (es)	2015-02-20	Sistema de administración de fármacos por dosis controladas
JP2000507613A (ja)	2000-06-20	Ｄｆｍｏ含有持続放出配合物
US9283214B2 (en)	2016-03-15	Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en)	2017-03-28	Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en)	2019-05-21	Methods of treatment of attention deficit hyperactivity disorder
CA2758556A1 (en)	2013-05-17	Pharmaceutical composition of amphetamine mixed salts
US20260027063A1 (en)	2026-01-29	Compositions for Treatment of Attention Deficit Hyperactivity Disorder
CN104220064B (zh)	2017-10-10	一种含辛弗林和托吡酯的联合产品
US10905652B2 (en)	2021-02-02	Compositions for treatment of attention deficit hyperactivity disorder
HK1075828B (en)	2011-03-18	Sustained released delivery of amphetamine salts